The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it will not be funded by the French social security system. Danish ...